Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10, Tieyi Road, Yangfangdian Street, Haidian District, Beijing, 100038, China.
World J Surg Oncol. 2024 May 31;22(1):144. doi: 10.1186/s12957-024-03426-1.
Hepatocellular carcinoma with peritoneal metastasis (HCC-PM) has a poor outlook. Traditional treatments have limited effect on survival. The safety and efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) have been shown in other peritoneal cancers. This study evaluates the role of CRS + HIPEC in HCC-PM.
A retrospective analysis of HCC-PM patients treated with CRS + HIPEC at Beijing Shijitan Hospital from March 2017 to December 2023 was conducted, assessing clinical features, severe adverse events (SAEs), and overall survival (OS) rates.
The study population comprised 10 HCC-PM patients who underwent CRS + HIPEC. The median peritoneal cancer index (PCI) was 25, and complete cytoreduction (CC0 ~ 1) was achieved in half of the patients. Three patients experienced SAEs within 30 days postoperatively. The 1-year, 3-year, and 5-year OS rates were recorded as 89.0%, 89.0%, and 21.0% respectively, with a median OS1 of 107.8 months and OS2 of 49.9 months. The median progression-free survival (PFS) was 5.0 months.
The application of CRS + HIPEC offers significant benefits to patients with HCC-PM. A selected group of patients may achieve prolonged PFS. Incorporating CRS + HIPEC into the treatment paradigm can thus be considered a strategic therapeutic option for patients with HCC-PM.
肝细胞癌伴腹膜转移（HCC-PM）预后较差，传统治疗方法对生存获益的影响有限。细胞减灭术联合腹腔热灌注化疗（CRS+HIPEC）在其他腹膜癌中的安全性和有效性已得到证实。本研究旨在评估 CRS+HIPEC 在 HCC-PM 中的作用。
对 2017 年 3 月至 2023 年 12 月在北京世纪坛医院接受 CRS+HIPEC 治疗的 HCC-PM 患者进行回顾性分析，评估临床特征、严重不良事件（SAE）和总生存（OS）率。
研究人群包括 10 例 HCC-PM 患者，均接受了 CRS+HIPEC 治疗。腹膜癌指数（PCI）中位数为 25，半数患者达到完全肿瘤细胞减灭（CC0~1）。3 例患者术后 30 天内发生 SAE。1 年、3 年和 5 年 OS 率分别为 89.0%、89.0%和 21.0%，OS1 中位数为 107.8 个月，OS2 中位数为 49.9 个月。中位无进展生存期（PFS）为 5.0 个月。
CRS+HIPEC 的应用可为 HCC-PM 患者带来显著获益，部分患者可获得更长的 PFS。因此，将 CRS+HIPEC 纳入治疗方案可被视为 HCC-PM 患者的一种治疗策略。
